Levetiracetam

Phase 3

Laboratorios Farmaceuticos Rovi, S.A./ADR (LRVIY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

5 competitors in Epilepsy

JAZZGWP42003-P 20 mg/kg/day Dose

Drug Information

Target Indication

Epilepsy

Clinical Trial

NCT01392768

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

LRVIY

Laboratorios Farmaceuticos Rovi, S.A./ADR

Biotechnology•North America•NASDAQ

Related Pipeline

Depigoid Parietaria judaica 1000DPP/mlPhase 3

Allergic Rhinoconjunctivitis

Glucosamine and chondroitin sulfate combination (Eurofarma)Phase 3

Osteoarthritis of Knee

Minoxidil Topical FoamPhase 3

Alopecia

Study group - quadrivalent recombinant hemagglutinin influenza vaccinePhase 3

Influenza, Human

Chlorthalidone 25 mg + amiloride hydrochloride 5 mgPhase 3

Arterial Hypertension

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts